Founded in July 2008, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease.  It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor proteins (TCRs) as a means of strengthening natural patient T cell responses.  Adaptimmune holds an exclusive licence to the use of this unique T cell receptor engineering technology in adoptive T cell therapy from its sister company, Immunocore Ltd. (formerly Avidex/MediGene).  In the US, Adaptimmune has an ongoing clinical trial in HIV as well as multiple ongoing oncology trials.

Backed by private investors and located alongside Immunocore Ltd. in its South Oxfordshire facilities, Adaptimmune operates a virtual business model with a small, focused management and scientific team and strong academic collaborations for rapid translation to the clinic. Recently, Adaptimmune LLC was founded in the US to aid in the management of the clinical programmes.